New Protein MRI Contrast Agent Developed for Liver Cancer Imaging
By MedImaging International staff writers Posted on 01 Jun 2015 |
The results of a study published in the May, 13, 2015, online issue of the Proceedings of the National Academy of Sciences of the United States of America (PNAS) reveal the development of a novel, and much more effective Magnetic Resonance Imaging (MRI) contrast agent, named ProCA32.
The researchers from the Georgia State University (Atlanta, GA, USA) and other institutions in Atlanta anticipate that the new protein-based MRI contrast agent and associated imaging methodology could help earlier detection of liver cancer, and other liver diseases. Existing contrast agents and imaging techniques are not sensitive and robust enough to diagnose primary and metastatic liver cancers early enough, and show poor treatment responses, and result in high mortality rates.
ProCA32 shows high stability for Gadolinium (Gd3+) and a 1011-times increased selectivity for Gd3+ over Zinc (Zn2+) compared with existing contrast agents, and can be used to detect early-stage micro-metastatic liver tumors. Using T1- and T2-weighted and T2/T1 ratio robust MRI imaging, the researchers were able to detect early liver metastases ∼0.24 mm in diameter. The current detection size limit is 10–20 mm.
The new contrast agent has additional properties that make it suitable for high-quality imaging, and could be a breakthrough, not only for early detection of primary and metastatic liver cancers, but also for treatment monitoring, and guiding therapeutic interventions, such as drug delivery.
Related Links:
Georgia State University
The researchers from the Georgia State University (Atlanta, GA, USA) and other institutions in Atlanta anticipate that the new protein-based MRI contrast agent and associated imaging methodology could help earlier detection of liver cancer, and other liver diseases. Existing contrast agents and imaging techniques are not sensitive and robust enough to diagnose primary and metastatic liver cancers early enough, and show poor treatment responses, and result in high mortality rates.
ProCA32 shows high stability for Gadolinium (Gd3+) and a 1011-times increased selectivity for Gd3+ over Zinc (Zn2+) compared with existing contrast agents, and can be used to detect early-stage micro-metastatic liver tumors. Using T1- and T2-weighted and T2/T1 ratio robust MRI imaging, the researchers were able to detect early liver metastases ∼0.24 mm in diameter. The current detection size limit is 10–20 mm.
The new contrast agent has additional properties that make it suitable for high-quality imaging, and could be a breakthrough, not only for early detection of primary and metastatic liver cancers, but also for treatment monitoring, and guiding therapeutic interventions, such as drug delivery.
Related Links:
Georgia State University
Latest MRI News
- Low-Cost Whole-Body MRI Device Combined with AI Generates High-Quality Results
- World's First Whole-Body Ultra-High Field MRI Officially Comes To Market
- World's First Sensor Detects Errors in MRI Scans Using Laser Light and Gas
- Diamond Dust Could Offer New Contrast Agent Option for Future MRI Scans
- Combining MRI with PSA Testing Improves Clinical Outcomes for Prostate Cancer Patients
- PET/MRI Improves Diagnostic Accuracy for Prostate Cancer Patients
- Next Generation MR-Guided Focused Ultrasound Ushers In Future of Incisionless Neurosurgery
- Two-Part MRI Scan Detects Prostate Cancer More Quickly without Compromising Diagnostic Quality
- World’s Most Powerful MRI Machine Images Living Brain with Unrivaled Clarity
- New Whole-Body Imaging Technology Makes It Possible to View Inflammation on MRI Scan
- Combining Prostate MRI with Blood Test Can Avoid Unnecessary Prostate Biopsies
- New Treatment Combines MRI and Ultrasound to Control Prostate Cancer without Serious Side Effects
- MRI Improves Diagnosis and Treatment of Prostate Cancer
- Combined PET-MRI Scan Improves Treatment for Early Breast Cancer Patients
- 4D MRI Could Improve Clinical Assessment of Heart Blood Flow Abnormalities
- MRI-Guided Focused Ultrasound Therapy Shows Promise in Treating Prostate Cancer